You raise an interesting point here haydenbd. I've often wondered what the share price would be today if it was just ADAPT and Cardiocel.
These vac clinical trials are incredibly expensive and the results are unknown. With an already large cash burn evident over the past 6 months (as viewed by the past two 4c's) one has to wonder how long investors appetite will hold.
Vaxxas secures funding interest to see if professor Fraser utilizes nanopatch, page-46
-
- There are more pages in this discussion • 72 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.00 |
Change
0.000(0.00%) |
Mkt cap ! $346.0M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.10 | $17.70 | $58.64K | 3.27K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 109 | $18.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.10 | 700 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |